ly3819469
Nucleic acidexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jun 14, 2021 (NCT04914546)
Timeline
Indications
Mechanism of action
- Apolipoprotein A-IANTISENSE INHIBITOR
APOA1 antisense inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068446 ↗
- ChEMBLCHEMBL6068445 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06916078 | Phase 1 | Apr 23, 2025 | Eli Lilly |
| NCT06292013 | Phase 3 | Mar 5, 2024 | Eli Lilly |
| NCT05932446 | Phase 1 | Jun 30, 2023 | Eli Lilly |
| NCT05841277 | Phase 1 | Apr 25, 2023 | Eli Lilly |
| NCT05565742 | Phase 2 | Oct 20, 2022 | Eli Lilly |
| NCT04914546 | Phase 1 | Jun 14, 2021 | Eli Lilly |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 6 | 6 | 3 | 2021 |
1 organizations
Page 1 / 1